Lung Cancer Trials

CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

• Men or women, ages 18 and older, diagnosed with limited-stage small-cell lung cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

SWOG 1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

• Men or women, ages 18 and older, diagnosed with squamous cell non-small cell lung cancer; disease must be either advanced, stage IIIB or IV. For additional criteria, call our Clinical Trials office at (910) 715-2200.

NRG-LU001: Chemotherapy and Radiation Therapy with or without Metformin Hydrochloride in Treating Patients with Stage III Non-small Cell Lung Cancer

• Men or women, ages 18 and older, diagnosed with Stage IIIA or IIIB non-small cell lung cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

RTOG 1306: Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer (NSCLC)

• Men or women, ages 18 and older, newly diagnosed with Stage IIIA or IIIB non-squamous NSCLC.  For additional criteria, call our Clinical Trials office at (910) 715-2200.

ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

• Men or women, ages 18 or older, diagnosed with Stage IIIA, II or large IB non-small cell lung cancer (NSCLC).  For additional criteria, call our Clinical Trials Office at (910) 715-2200.

GO29436 (IMpower150):A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

• Men or women, ages 18 or older, diagnosed with Stage IV non-small cell lung cancer (NSCLC).  For additional criteria, call our Clinical Trials Office at (910) 715-2200.

Checkmate 370: A Master Protocol of Phase 2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies

• Men or women, ages 18 and older, diagnosed with locally advanced or stage IV non-small cell lung cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

• Atrial Fibrillation
• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Fallopian Tube Cancer
• Colorectal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Venous Thromboembolism - Cancer Related
• Lymphomas
• Kidney Cancer
• Lung Cancer
• Multiple Myeloma
• Ovarian Cancer
• Peritoneal Cancer
• Prostate Cancer
• Solid Tumors